In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, explains why the real technology challenge isn't usability alone—it's making it easier for patients and sites to interact more effectively with each other.
|Articles|January 21, 2014
Clinverse and Datatrak Announce Strategic Partnership
Clinverse, Inc. has established a strategic partnership with Datatrak.
Advertisement
Clinverse, Inc., has established a strategic partnership with Datatrak. The partnership integrates Clinverse's ClinPay® solution with Datatrak ONE® solution. ClinPay automates the entire financial lifecycle of global clinical trials, while the Datatrak ONE solution allows sponsors and CROs to obtain higher quality data faster. By integrating both systems, sponsors and CROs can:
- Further streamline the payment process
- Reduce workload, time, and related costs
- Trigger payments based on actual data entered into EDC system
You can read the full release
Advertisement
Related to this article
In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across workflows, and FDA's approval of a gene therapy for a rare childhood syndrome.
In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, shares what she expects to be at the center of the conversation—from building trust between patients and sites to where AI may and may not have a role in that relationship.
A platform-based approach connects AI across workflows, data and governance, helping life sciences organizations move from isolated wins to real scale.
In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system integration not models, and how regulators across three jurisdictions are formalizing patient input requirements.
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
Why clinical development’s next AI bottleneck is not the model, but the system around it.
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more than sourcing strategy, and how early readiness signals predict trial risk.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
How a Platform Approach Can Scale AI’s Impact in Life Sciences
2
Benchmarking Study Finds Clinical Trial Performance Is Shaped by Operating Model Design, Not Sourcing Strategy
3
DPHARM 2026: What the Patient-Site Relationship Needs Most Right Now
4
Lessons from Hundreds of Clinical Trials: AI’s Successes, Gaps, and Opportunities
5